Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and Gefitinib in Advanced EGFR Mutant Lung Cancer
NCT03122717Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2017
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and gefitinib in non-small cell lung cancer (NSCLC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Number of patients completing combination therapy at 3 years. Started May 2017; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03122717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122717.